Skip to content
Jagsonpal Pharmaceuticals logo

Jagsonpal Pharmaceuticals

JAGSNPHARM NSE
₹221.57 No trade today
P/E
32.39
View as Markdown
MCP
Close 4 Nov 2026 ₹221.57 +4.91 +2.27% 1Y
Start ₹216.66

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
22.70%
Debt to Equity
0.03
EPS (TTM)
₹6.84
Book Value
₹36.91
Market Cap
—
P/E (TTM)
32.39
P/B
6.00
ROE
17.30%
Dividend Yield
1.85%
EBITDA
₹70.10 Cr
52W High
₹264.50
52W Low
₹155.00
Volume
0

Peer Comparison

Healthcare › Pharmaceuticals

Jagsonpal Pharmaceuticals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Jagsonpal Pharmaceuticals (this company)
₹221.5732.39₹1,436 Cr6.001.85%17.30%22.70%₹294 Cr₹46 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr5.390.70%16.90%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

55 Good

Data confidence 100/100

Category scores

Quality
68
Strong
Returns, margins, earnings quality 22% weight
Valuation
51
Average
Cheap vs sector & own history 24% weight
Growth
19
Poor
Sales & profit trajectory 9% weight
Financial Health
90
Strong
Solvency, leverage, coverage 9% weight
Momentum
40
Weak
Trend strength, vol-adjusted 12% weight
Ownership
49
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 50.3%
  • Company's working capital requirements have reduced from 24.0 days to 11.0 days

Weaknesses

1
  • The company has delivered a poor sales growth of 8.85% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish577
OscillatorsBullish072
Moving AveragesNeutral505

Key readings

RSI (14)
48.03
Neutral
MACD (12,26,9)
−3.03
Bullish
SMA (50)
229.86
Bearish
SMA (200)
208.45
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+7.21%
5Y+8.83%
3Y+6.59%
1Y+6.69%
TTM+3.17%

Net profit

Net profit growth by window
10Y+30.51%
5Y+20.39%
3Y+16.78%
1Y−21.82%
TTM−24.59%

Operating cash flow

Operating cash flow growth by window
10Y+17.97%
5Y+10.91%
3Y0.00%
1Y−14.55%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+11.82 pp
5Y+10.10 pp
3Y+5.86 pp
1Y+1.25 pp
TTM+1.11 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹144 Cr
Mar 2018₹127 Cr
Mar 2019₹167 Cr
Mar 2020₹159 Cr
Mar 2021₹188 Cr
Mar 2022₹218 Cr
Mar 2023₹237 Cr
Mar 2024₹209 Cr
Mar 2025₹269 Cr
Mar 2026₹287 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹12.00 Cr
Mar 2018−₹12.00 Cr
Mar 2019₹7.00 Cr
Mar 2020₹8.00 Cr
Mar 2021₹17.00 Cr
Mar 2022₹19.00 Cr
Mar 2023₹27.00 Cr
Mar 2024₹22.00 Cr
Mar 2025₹55.00 Cr
Mar 2026₹43.00 Cr

Quarterly Results

₹ Cr
JAGSNPHARM quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
60
58
47
43
61
75
74
59
76
74
73
64
82
81
Expenses
52
49
44
41
51
58
58
50
61
58
57
53
65
65
Operating Profit
9
8
3
3
10
16
16
9
14
16
16
11
17
—
OPM %
14%
14%
7%
6%
17%
22%
21%
15%
19%
22%
22%
17%
21%
—
Other Income
2
2
3
2
−2
2
26
3
3
3
1
3
3
—
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
1
2
2
2
2
2
2
2
2
2
PBT
10
10
5
5
7
15
39
9
14
17
15
12
18
17
Tax %
26%
25%
25%
22%
25%
25%
17%
24%
25%
25%
25%
25%
25%
25%
Net Profit
7
7
4
4
5
11
32
7
11
13
11
9
13
13
EPS (₹)
1.14
1.14
0.6
0.54
0.81
1.73
4.82
0.99
1.62
1.89
1.64
1.31
2
—

Sep 2026: from the results filed on 28 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
JAGSNPHARM profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
138
143
144
127
167
159
188
218
237
209
269
287
294
Expenses
129
132
138
138
157
150
169
192
203
186
218
229
233
Operating Profit
9
12
6
−11
9
9
19
26
34
23
51
58
61
OPM %
6%
8%
4%
−9%
6%
5%
10%
12%
14%
11%
19%
20%
21%
Other Income
0
1
13
0
1
3
4
3
2
9
28
10
10
Interest
4
5
3
1
1
1
1
0
0
1
1
1
1
Depreciation
3
3
2
0
1
1
1
2
1
2
8
9
9
PBT
2
4
14
−12
9
9
22
27
35
30
70
58
61
Tax %
30%
20%
18%
−1%
20%
16%
22%
29%
23%
25%
21%
25%
—
Net Profit
1
3
12
−12
7
8
17
19
27
22
55
43
45
EPS (₹)
0.18
0.5
1.81
−1.76
1.1
1.2
2.6
2.88
4.08
3.4
8.34
6.43
6.84
Div. Payout %
22%
8%
2%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
9%
17%
15%
56%
49%
59%
30%
62%
—

Balance Sheet

₹ Cr
JAGSNPHARM balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
13
13
13
13
13
13
13
13
13
13
13
13
Reserves
82
85
97
85
91
98
109
120
146
174
227
263
Borrowings
39
38
8
8
4
5
7
0
6
9
9
8
Other Liabilities
19
22
25
23
28
31
35
31
30
21
29
32
Total Liabilities
154
159
143
130
136
147
164
164
195
217
278
317
Fixed Assets
52
52
22
21
22
22
26
23
24
9
94
85
CWIP
0
0
0
3
4
4
0
0
0
0
0
0
Investments
0
0
0
0
0
11
15
51
1
0
0
0
Other Assets
102
108
121
105
110
109
123
91
170
208
184
231
Total Assets
154
159
143
130
136
147
164
164
195
217
278
317

Cash Flow

₹ Cr
JAGSNPHARM cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
4
9
−3
−2
31
11
28
7
47
35
55
47
Investing
0
−2
41
−3
−1
−11
−2
−26
−58
−25
−45
−36
Financing
−1
−6
−34
−1
−6
−1
−7
−18
0
−9
−12
−12
Net Cash Flow
2
1
5
−6
24
0
19
−36
−11
2
−2
−1
Free Cash Flow
4
6
40
−5
30
12
28
6
48
35
90
47
CFO/EBITDA
53
83
−6
14
311
150
164
54
158
189
124
101

Ratios

JAGSNPHARM financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
119
106
100
73
45
49
25
26
32
19
18
22
Inventory Days
176
246
295
307
164
191
134
122
82
68
58
51
Days Payable
42
60
56
54
59
76
82
76
66
35
37
40
Cash Conversion Cycle
252
292
339
325
150
164
77
72
48
53
39
33
Working Capital Days
68
72
154
149
67
55
32
59
34
52
9
11
ROCE %
5%
7%
3%
−10%
9%
9%
18%
20%
25%
17%
23%
23%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Jagsonpal Pharmaceuticals insights

67 extracted metrics across FY08–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 68.81%
  • Public 18.85%
  • Others 8.56%
  • FIIs 2.14%
  • DIIs 1.65%

No promoter shares pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Jagsonpal Pharmaceuticals

What does Jagsonpal Pharmaceuticals Ltd do?
Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients
Where is Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) listed?
Jagsonpal Pharmaceuticals Ltd trades as JAGSNPHARM on the NSE and under code 507789 on the BSE.
Which sector does Jagsonpal Pharmaceuticals Ltd belong to?
Jagsonpal Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd trades at a PE ratio of 32.39 as of 4 Nov 2026, on earnings per share of ₹6.84, against a book value of ₹36.91 per share.
What is the 52-week high and low of Jagsonpal Pharmaceuticals Ltd?
Over the last 52 weeks Jagsonpal Pharmaceuticals Ltd has traded between ₹155 and ₹264.5 as of 4 Nov 2026.
Does Jagsonpal Pharmaceuticals Ltd pay dividends?
Jagsonpal Pharmaceuticals Ltd has a dividend yield of 1.85%.
What is the Return on Equity (ROE) of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd reported a return on equity of 17.30%. Its debt-to-equity ratio is 0.03.

Company Information

Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients

Website jagsonpal.com
CEO Mr. Manish Gupta
Employees 1,399
Listed 1 Mar 2000
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JAGSNPHARM.md for Jagsonpal Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month